New Gout Drug Krystexxa Exceeds Target

September 2, 2011 by Alex.

Gout foot
Gout foot
There is increased hope for the roughly 3% of chronic, severe gout sufferers who do not respond to current gout medications. In recent phase III trials of the new gout medication Krystexxa, an impressive 42% of refractory gout patients achieved statistically significant reductions in uric acid levels, and sustained them for six months. This exceeeded the target amount set for the study by the drug's manufacturer, Savient Pharmaceuticals. In contrast, those gout patients in the trial that received a placebo saw no reduction in uric acid levels.

"When you have seriously ill people who have no options, 40 percent is pretty good," said Dr. Michael Becker from the University of Chicago," author of the latest study, which was published in the Journal of the American Medical Association. "Gout can be a really serious and disabling disease."

Krystexxa (generic name plegloticase) was FDA approved in 2010 based on earlier clinical trials. The new gout medication, which is administered by intravenous infusion, is derived from an animal hormone. The pegloticase mechanism of action is different than that of other gout drugs - it converts uric acid to a nontoxic byproduct that is easily excreted in the urine.

High levels of uric acid are the cause of gout, an extremely painful form of arthritis. The excess acid crystallizes into needle sharp deposits in the joints, usually at the base of the big toe. The uric acid can also form knobby, chalky lumps called tophi. Tophi can be reabsorbed back into the body if uric acid levels are reduced. Forty percent of the trial participants with tophi experienced a resolution of one or more of the lumpy deposits.

Krystexxa is given intravenously over at least two hours every two weeks. The FDA has warned that patients should be given a corticosteroid and antihistamine before infusions because of a high risk of allergic reaction. Other common side effects of Krystexxa are gout flare ups (which occurred in 80% of the recent trial participants), nausea and vomiting, chest pain, constipation, nasal irritation and bruising at the injection site.

Krystexxa is not intended for use in the average gouty arthritis patient, most of which can be treated with more traditional gout medications such as Colcrys (generic colchicine) or Zyloprim (generic allopurinal). Currently, the new injectable gout drug costs about $5000 a month. It's hoped that gout patients who respond well to the treatment could eventually use cheaper gout medications.

Armed with these impressive new results, Savient Pharmaceuticals plans to amp up promotion of its new gout drug in the US and other countries. Up to now, their marketing efforts have largely been aimed at rheumatologists, but they now plan to expand their efforts to include primary care physicians. "This really now is the foundation for our launch of phase 2 into the primary care audience," said Savient Chief Executive Officer John Johnson.

Johnson says the pharmaceutical company "expects to see some acceleration in sales" as a result of their increased target market. The company is said to be disappointed in the $1.4 million dollars in net sales the gout medication generated in the first six months after receiving FDA approval.

Filed under: Gout Medications.

Tags: gout drug, krystexxa, gout medication, generic plegloticase, gout cause, gout tophi, side effects of krystexxa, generic allopurinal, zyloprim, colchicine, colcrys.

There are no comments for now. Leave your comments.

Anti-Gout Drug May Decrease Risk of Colon Cancer

September 6, 2011 by Lynn.

Allopurinol, a relatively inexpensive gout medication that has been on the market for more than 20 years, may have some activity against colorectal adenomas, or polyps, according to two separate studies. Most colorectal cancer develops from adenomatous polyps.

A large study in Israel showed that patients using allopurinol for gout had a lower risk of colorectal cancer than a control group not taking allopurinol. A second study in Italy appeared to confirm that the gout medicine protects against colon carcinogenesis. To read the full article on ScienceDaily, CLICK HERE.<

Filed under: Cancer, Gout Medications.

Tags: anti-gout drug, gout medication, allopurinol for gout, gout medicine, allopurinol,, colchicine.

There are no comments for now. Leave your comments.

Warning for Arthritis Patients Who Take NSAIDs

September 8, 2011 by Alex.

Relief from basykes
Relief from basykes
Gouty arthritis patients who take NSAIDs (non-steroidal anti-inflammatory drugs) such as naproxen or celecoxib for relief of pain and inflammation should be aware of the results of a recent study conducted at McMaster University's Farncombe Family Digestive Health Research Institute.

Researchers discovered that those patients who take stomach acid lowering drugs called proton pump inhibitors (PPIs) such as Nexium or Prevacid with their NSAIDs to reduce the chance of stomach bleeding or ulcers are at risk of a different problem - major damage to the small intestine.

It turns out that PPIs may actually aggravate hard to detect damage done to the small intestine by NSAIDs. This damage has only recently been revealed by the use of mini video cameras that are swallowed like pills.

"Suppressing acid secretion is effective for protecting the stomach from damage caused by NSAIDs, but these drugs seem to be shifting the damage from the stomach to the small intestine, where the ulcers may be more dangerous and more difficult to treat," warns principal investigator Professor John Wallace.

The use of probiotics (live microorganisms) is now being considered as a possible treatment for injury to the small intestine. In the meantime, arthritis and gouty arthritis patients may want to reconsider their use of gout medications.

Filed under: Gout Arthritis.

Tags: colchicine, gouty arthritis, gout medications, nsaids, non-steroidal anti-inflammatory drugs, colchicine medication, buy colchcine .

There are no comments for now. Leave your comments.

Three Ways Watermelons Fight Gout

September 12, 2011 by Estella.

from blue_jay1
from blue_jay1
The author of the blog Natural Gout Treatments has written a post on watermelon as a gout remedy. The associated Gout Health Newsletter includes a recipe for a "seriously awesome" watermelon salad. Simply slice or cube a watermelon, then add half a finely chopped red onion, feta cheese, a handful of fresh basil leaves and some quality olive oil.

To read more about watermelon as a possible gout remedy on the gout treatment blog, >CLICK HERE.<

Filed under: Gout Natural Remedies.

Tags: colchicine resource, natural gout remedies, gout treatments, gout remedy, gout treatment, buy colchicine.

There are 2 comment(s). Leave your comments.

C-Health Offers Helpful Gout Fact Sheet

September 13, 2011 by Estella.

Health section
Health section
C-Health,'s health section, is a highly ranked health news and information site. Every week the health information website updates the top health stories of the week, and highlights the top five conditions and top five medications.

The site contains extensive information on numerous conditions, presented in Fact Sheets, Expert Columns, Health Tools and videos. Of the 85 condition Fact Sheets, the one on gouty arthritis is the fifth most searched. The comprehensive gout Fact Sheet covers its causes, symptoms, complications, diagnosis, prevention and treatment (including using medications such as allopurinol and colchicine for gout).

The easy to read Fact Sheet is a helpful resource for any gouty arthritis sufferer, from the newly diagnosed to the veteran gout patient. To read up-to-date information about gouty arthritis on C-Health> Click Here.< .

Filed under: Gout Fact.

Tags: gouty arthritis, gout medications, gout information, gout fact, colchicine, colchicine for gout.

There are no comments for now. Leave your comments.

Gout Drug Colchicine Proves a Cancer

September 15, 2011 by Estella.

from squirrelcowdog
from squirrelcowdog
A new cancer drug based on the gout drug colchicine is proving to be a powerful cancer drug capable of quickly killing malignant tumors. The new drug, called ICT2588 for now, is being referred to as a "smart bomb" because it can directly target a tumor without harming surrounding healthy tissue.

Both the gout medication colchicine and the experimental ICT2588 are derived from the autumn crocus, or meadow saffron. Colchicine (brand name Colcrys) has been widely and successfully used to treat gouty arthritis for centuries. Colchicine was known to have the potential to fight cancer, but can be toxic at high doses. This experimental modified form is harmless to healthy tissue, but toxic to tumor blood vessels.

Scientists the University of Bradford in England found a way of keeping ICT2588 non-toxic until it comes into contact with a protein released by tumors, MMP1. Tumors release MMP to cut a path into surrounding tissue where they can develop new blood vessels. "Our novel delivery system uses the presence of this active MMP to activate the drug, which attacks and breaks down cancer blood vessels, destroying the tumor's lifeline," explains Professor Lawrence Patterson, head of research team that developed ICT2588.

"What is also novel about our approach is that we are effectively targeting the blood supply of the tumor," says Patterson, "If you can starve the tumor of that blood supply, then you can cut off its ability to grow and to move around the body."

ICT2588 was so successful in destroying breast, prostrate and bowel cancers in mice that over half the mice went into remission after just one treatment. There were no ill effects. Although ICT2588 has only been tested in animals so far, researchers are hoping to test it in humans within two years, and possibly even within 18 months. The drug is expected to be effective against all kinds of solid tumors.

Filed under: Cancer.

Tags: colchicine, gout drug colchicine, gout medication, brand name colcrys, gouty arthritis .

There are 1 comment(s). Leave your comments.

Gout Diet Tips From a Health and Nutrition Expert

September 19, 2011 by Lynn.

from Meenu A G
from Meenu A G
Health and nutrition expert Nicole Kuhl has written a column on gouty arthritis for the Santa Monica Daily Press. The column, titled Going, Going, Going, Gout was spurred by a recent Reuters article on the rapid increase in the number of Americans being diagnosed with this painful form of arthritis. The Reuters article linked the rise in gouty arthritis to a rise in obesity and associated metabolic and degenerative disorders.

Kuhl reassures gout patients that gout is one of the most controllable metabolic diseases, (gout responds well to lifestyle changes and gout medication such as generic colchicine>). As a nutritionist, she offers 10 dietary strategies to combat gout. Many of these strategies will be familiar to those with gout (avoid high purine food; drinks lots of water), but others might be new (eat for your metabolic type; avoid foods from the nightshade family).

To read Kuhl's gout diet strategies online, >Click Here.<

Filed under: Gout Food Diet.

Tags: gout diet, gouty arthritis, gout medication, generic colchicine, gout treatment,, colchicine.

There are 1 comment(s). Leave your comments.
Most Recent Posts